Skip to main content

Varicella Zoster Virus Infection

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

EuBiologics
EuBiologicsKorea - Seoul
1 program
1
EuHZVPhase 11 trial
Active Trials
NCT06409494Active Not Recruiting72Est. May 2026
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
MG1111N/A1 trial
Active Trials
NCT05664152Unknown250Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
EuBiologicsEuHZV
GC BiopharmaMG1111

Clinical Trials (2)

Total enrollment: 322 patients across 2 trials

Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years

Start: Jul 2024Est. completion: May 202672 patients
Phase 1Active Not Recruiting

An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Start: Feb 2023Est. completion: Jun 2023250 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.